London, May 14, 2026, 17:29 BST
- Haleon became UEFA Medical’s first Health Partner in a multi-year scientific collaboration.
- The deal targets football-related pain management and education for clinicians.
- Haleon shares ended slightly lower in London, with investors still weighing softer pain and respiratory sales.
Haleon PLC has become UEFA Medical’s first Health Partner, giving the maker of Voltaren and Sensodyne a new football medicine platform as it tries to keep its over-the-counter pain business visible in a tougher consumer health market.
The company and UEFA said the multi-year partnership will focus on evidence-based pain management, including topical treatments, digital learning modules and webinars for medical teams. Topical non-steroidal anti-inflammatory drugs, or NSAIDs, are pain-relief medicines applied to the skin rather than swallowed.
The timing matters. Haleon’s pain relief sales fell 0.3% on an organic basis in the first quarter, while respiratory health dropped 3.4% after a weak cold and flu season. Oral health was the bright spot, rising 8.3%, led by Sensodyne and parodontax.
Haleon is trying to turn sports medicine into a broader brand channel. Fierce Pharma said the UEFA Medical tie-up follows a March deal making Voltaren an official UEFA Champions League licensed product and a U.S. Soccer Federation marketing push the following month.
UEFA’s chief of medical and anti-doping, Dr Zoran Bahtijarević, said the partnership gives UEFA and Haleon a “valuable framework” to develop evidence-based guidance for clinicians and medical teams. Eran Gefen, Haleon’s head of medical and scientific affairs for OTC, said the company’s role was to bring medical expertise to care for active people. Uefa
Haleon did not disclose financial terms. That leaves investors to judge the deal less as a near-term earnings driver and more as a brand and professional-education play around Voltaren, Advil and other pain-relief products.
The wider market is not easy. Reuters reported last month that Haleon warned of rising freight costs and kept its 2026 outlook after weak cold and flu demand held first-quarter organic revenue growth to 2.2%, just below company-compiled analyst consensus. Reckitt, a rival in consumer health and household products, also cited weak cold and flu demand in the United States and Europe.
Kenvue, another consumer health peer and the maker of Tylenol, reported a 2.3% organic sales decline in self-care in its first quarter, saying weak cold and flu seasons across major markets weighed on that unit. That suggests Haleon is not alone in dealing with softer seasonal demand.
But Haleon has kept returning cash. The company said it allocated 500 million pounds to share buybacks in 2026 and had completed about 36% of that plan by late April. A filing this week showed it bought 10.2 million ordinary shares for cancellation between May 5 and May 8.
Shares still lagged on the day. Hargreaves Lansdown data showed Haleon at 329.5 pence to sell and 329.6 pence to buy after the London close, down 0.21%, while the FTSE 100 was up 0.46%. The platform put Haleon’s market value at about 29.18 billion pounds.
The risk is that a science-led football partnership may help Haleon’s profile without quickly lifting sales. Cold and flu weakness, freight costs and pressure on household budgets remain more immediate tests for the group’s 2026 guidance.
For now, the UEFA deal gives Haleon a sharper sports-medicine story. The harder part is proving it can move the numbers.
